Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole + itopride
- Development stage
- Unknown
- Lead developer
- Thrift Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZESPEA-IT is an oral fixed-dose combination capsule developed and marketed by Thrift Pharmaceuticals. It contains enteric-coated rabeprazole sodium (20 mg), a proton pump inhibitor (PPI), and sustained-release itopride hydrochloride (150 mg), a prokinetic agent. Rabeprazole suppresses gastric acid secretion by covalently binding to and inhibiting the gastric H+/K+-ATPase (proton pump) in parietal cells. Itopride enhances gastrointestinal motility and provides antiemetic effects through its dual mechanism of action as a dopamine D2 receptor antagonist and an acetylcholinesterase inhibitor. This combination is primarily indicated for the management of gastroesophageal reflux disease (GERD), functional dyspepsia, and associated symptoms such as heartburn, acid regurgitation, bloating, and nausea.
- Brand names
- ZESPEA-IT
- Other names
- rabeprazole and itopriderabeprazole and itopride hydrochloriderabeprazole sodium + itopride hydrochloriderabeprazole sodium and itopriderabeprazole sodium and itopride hydrochloride
02
Targets
AcetylcholinesteraseDRD2 (Dopamine D2 Receptor)CHRM3 (M3)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on rabeprazole + itopride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole + itopride.